Avenzo Therapeutics to present first ORION-1 Phase 1 data for selective CDK4 inhibitor AVZO-023
Avenzo will present first ORION-1 data for AVZO-023 in December, testing whether selective CDK4 inhibition offers a better tolerability profile.
Pharma & Biotech
Pharma & Biotech
Avenzo Therapeutics to reveal VBC103 Phase 1 results at ESMO Asia 2026
Avenzo's partner VelaVigo will disclose early human safety and efficacy findings for the Nectin-4/TROP2 antibody-drug conjugate VBC103 at ESMO Asia 2026. The presentation could clarify the clinical potential of dual-antigen targeting, while a separate United States study advances in urothelial cancer.
Pharma & Biotech
What Avenzo Therapeutics’ ORION-1 expansion reveals about the next phase of CDK drug development
Find out how Avenzo Therapeutics’ AVZO-023 and AVZO-021 combination study could influence HR+/HER2- breast cancer treatment.
Pharma & Biotech
AVZO-021 at ASCO 2026: what updated Phase 1 results could reveal about Avenzo Therapeutics’ CDK2 strategy
Avenzo Therapeutics will present updated AVZO-021 Phase 1 data at ASCO 2026. Read why the CDK2 story could matter for breast cancer and beyond.
Pharma & Biotech
Is Avenzo’s AVZO-021 the next big player in HR+/HER2- metastatic breast cancer?
Avenzo shares Phase 1 data on CDK2 inhibitor AVZO-021 in HR+/HER2- breast cancer. Find out what it means for post-CDK4/6 resistance strategies in 2025.